



ORIGINAL ARTICLE

## Outcome of diode laser vaporization for high risk patients with benign prostatic hyperplasia.

Shahid Ali<sup>1</sup>

**Article Citation:** Ali S. Outcome of diode laser vaporization for high risk patients with benign prostatic hyperplasia. Professional Med J 2023; 30(11):1391-1397. <https://doi.org/10.29309/TPMJ/2023.30.11.7492>

**ABSTRACT.... Objective:** To determine the outcome of laser vaporization of prostate using diode at 980/1470 nm for the treatment of BPH among high risk patients. **Study Design:** Longitudinal Observational Study. **Setting:** Shalamar Hospital, Lahore. **Period:** June 2009 till June 2022. **Material & Methods:** Total of 500 patients with associated co-morbid illnesses and benign prostate hyperplasia not responding to medical therapy, failed trial without catheter, chronic urinary retention, refusal for TURP were assessed for eligibility to enter the study. Inclusion criteria were patients with refractory urinary retention, chronic urinary retention, failure of previous medical treatment. Exclusion criteria were patients with neurogenic bladder, carcinoma of prostate, carcinoma of bladder, abnormal digital rectal examination, known neurological disorder or history of spinal cord injury also were excluded from study. **Results:** The patients' mean age was  $68.57 \pm 7.98$  years, Baseline mean maximum urinary flow rate was  $5.57 \pm 2.44$  mL/s, post void residual was  $130.91 \pm 24.18$  mL, and international prostate symptom score was  $26.09 \pm 2.40$  at preoperative. At 3 months follow-up, Qmax was  $23.31 \pm 8.0$ , PVR was  $22.43 \pm 5.21$  and IPSS was  $7.27 \pm 1.42$ . On the other hand, mean Qmax was  $25.83 \pm 6.84$  mL/s, PVR was  $18.38 \pm 4.53$  mL, and IPSS was  $5.29 \pm 0.61$  at 6 months follow-up. **Conclusion:** Treatment of BPH by 980/1470 nm diode laser have effective and safe clinical outcome for high risk patients as we found significant improvements in Qmax, IPSS, and PVR at 3 months and 6 months follow up.

**Key words:** Lasers, Prostatic Hyperplasia, Semiconductor Diode Lasers, Treatment Outcome, Vaporization.

### INTRODUCTION

Photo-selective vaporization of the prostate has been introduced as one of gold standards of care in the treatment and management of benign prostatic hyperplasia.<sup>1</sup> Benign Prostatic Hyperplasia (BPH) is a condition in men in which the prostate tissues become enlarged but not cancerous. BPH is also termed as Benign Prostatic Obstruction (BPO). There are several surgical methods have been developed to treat BPH in elderly men such as transurethral resection of prostate (TURP). There has been massive growth in the prevalence of BPH with an increase in elderly men population and hope for better quality of treatment. Despite TURP has a higher rate of success, operative safety and perioperative morbidity specifically in terms of bleeding have posed a serious threat to the

quality of life.<sup>2</sup> Additionally, Qian  $\square$  et al. stated that transurethral resection syndrome and retrograde ejaculation due to irrigant absorption are the major complications associated with the TURP that have reduced the success and effectiveness of TURP in the BPH treatment.<sup>3</sup> The technical advancements for BPH treatment with TURP have not made sufficient improvement in the safety of TURP and rate of blood transfusion, retrograde ejaculation, prolonged catheterization time, bladder neck contractures, and urethral strictures are still high. With regard to it, alternatives to TURP treatment is required that provide similar clinical outcomes with fewer complications.

LVP (Laser Vaporization of Prostate) is one of the effective alternative treatment method to TURP that creates different effects in prostate tissues,

1. MBBS, FCPS (Urology), Senior Registrar Urology, Shalamar Hospital Lahore.

**Correspondence Address:**  
Dr. Shahid Ali  
Department of Urology,  
Shalamar Hospital Lahore.  
imshahiduro@gmail.com

**Article received on:** 18/03/2023  
**Accepted for publication:** 31/08/2023

including vaporization and coagulation. In the treatment of BPH, different types of laser such as holmium, potassium-titanyl phosphate (KTP), thulium, and diode have been available.<sup>4</sup> Among these, PVP through holmium and KTP laser has acquired more popularity. Multiple laser devices at different wavelength have been developed to be used in the treatment of BPH. PVP using KTP laser is working at the wavelength of 532 nm and providing efficient vaporization of prostate. It is stated that PVP through KTP laser at 532 nm provides efficient hemostasis due to its ability to get absorbed greatly by hemoglobin.<sup>5</sup> However, it has minimal absorption in water that cause slow ablation and prolonged operation time. In this regard, the semiconductor diode laser has found to be the best due to its hemostatic properties. However, due to its severe complications such as pain, dysuria, and urinary symptoms, it is less preferable in BPH the treatment. A newly developed diode laser working on the wavelength of 980 nm is thought to be efficient for the treatment of BPH due to its significant absorption in hemoglobin and water causing high ablative properties of tissues, new fiber design, and effectual hemostasis.<sup>6</sup> Moreover, laser vaporization of prostate using diode at 980 nm has reduced risk of perioperative complications and reduced stay at the hospital.

Considering this, the aim of this research is to assess the outcome of laser vaporization of prostate using diode at 980 nm for the treatment of BPH.

## **MATERIAL & METHODS**

### **Patients**

Five hundred high risk patients from Shalamar Hospital were included within the duration of 14 years from June 2009 till June 2022 after approval from ethical committee (18.03.23). Patients associated with co-morbid illnesses and benign prostate hyperplasia not responding to medical therapy, failed trial without catheter, chronic urinary retention, refusal for TURP were assessed for eligibility to enter the study. Preoperative workup includes routine blood chemistry including prostate specific antigen, complete blood count, serum creatinine and urea, serum

electrolytes, bleeding profile, urine analysis and culture sensitivity, ECG, chest x-ray, digital rectal examination and transrectal ultrasound was performed to estimate the size of prostate. IPSS was completed by self assessment. Inclusion criteria were patients of ASA-III, ASA-IV with refractory urinary retention, chronic urinary retention, failure of previous medical treatment. Exclusion criteria were fit patients of ASA-I or ASA-II with neurogenic bladder, carcinoma of prostate, carcinoma of bladder, abnormal digital rectal examination, known neurological disorder or history of spinal cord injury also were excluded from study. A systematic assessment was performed for all patients with detailed medical history, clinical examination and routine laboratory and imaging workup. Residual volume, Urine culture and TRUS were done in all patients. the average prostate volume was 45-120ml, and the residual volume was 150±80ml. Assessment of anesthesia risk was performed with American society of anesthesiologists (ASA) score.

### **Mode of Anesthesia**

Regional anesthesia was given to all patients with intensive monitoring of vitals heart rate, blood pressure, oxygen saturation and ECG.

### **Surgical Method**

The non-contact Diode laser was employed. All models are from the same manufacturer i.e Biolitec . either straight side firing or twister side firing laser fibers with a 600mm core diameter was placed in cavity through a modified resectoscope with continuous flow sheath with physiological saline as irrigation fluid. Laser output power could be adjusted from 05 to 200 watts however we used powers between 50 -120 watts, rarely 140 watts. Vapo-resection technique was adapted. With this technique we never needed to jump over to higher levels than these power settings. In medium sized prostatic enlargement we started ablating from median lobe at bladder neck working in circular motion, gradually proceeding on both lateral lobes up to verumontanum.

In larger glands modified Butterfly technique was adapted. (giving multiple longitudinal ablative groves extending from neck to distal end of

prostate, along with performing vaporesction where ever needed). It saved our operative time and more over provided adequate biopsy material for histological examination. Median lobe if grossly enlarged was dealt with by first coagulating / ablating its neck with too and fro motion from both right and left sides. Once it was seen to be blood less, then it was resected out easily with resectoscope. Our custom build instruments allowed us with the advantage of obviating the need for changing outer and inner sheath of rescetoscope once they have been introduced at the beginning of the procedure. Only the working element needed to be interchanged when switching over from ablation to resection mode. Thus making the procedure less cumbersome, much easier and quicker. before coming out we had made a principle to slowly irradiate the whole prostatic bed with low watt laser (20-50 watts) under low irrigant flow, thus stopping even the smallest visible bleeders at the end. As all of our patients were high risk cases so after surgery a three way foley catheter was left in place to irrigate the bladder postoperatively for a day. However, we were not in a hurry to remove foleys catheter in these patients and it was removed usually with in a week. Bladder drill was advised in patients with history of prolonged pre operative catheterization (one of our patient had been catheterized for more than three years). Mostly in all instances the patients were discharged on next day with Foley catheter and removal advised depending upon the condition of the patient. Post void residual urine was assessed the next day after catheter removal and patient was called back on 8th day, at month intervals for 2 to 3 months and 6 months again assessed for post void residual and IPSS.

### Statistical Analysis

Data were analyzed using SPSS version 27. The mean and standard deviation were calculated for the quantitative variable. Frequency and percentage were calculated for qualitative variables. Mean comparsion was done by independent t-test. p value  $\leq 0.05$  was considered significant.

### RESULTS

A total of 500 patients were enrolled in this study

who were not responding to medical treatment and refused to take TURP treatment for BPH. Out of 500 patients, 4 patients were lost to follow and 496 patients were enrolled in the study. Table-I illustrates the baseline characteristics of the patients enrolled in this study. The patients' mean age  $\bar{x}$  was  $68.57 \pm 7.98$  years, while body mass index was  $23.82 \pm 2.40$  kg/m<sup>2</sup>. The mean prostate size of the patients was  $89.66 \pm 22.36$  mL, operation time was  $45.25 \pm 8.92$ , catheterization time was  $43.72 \pm 8.46$  min. The mean prostate-specific antigen (PSA) was  $2.09 \pm 0.48$  ng/mL, and mean hospital stay was  $5.95 \pm 1.81$  days. Out of 496 patients, post-operative complications found in 86 patients. 46 patients were complained of burning micturition, 11 patients experienced stress incontinence, and 29 patients were experiencing terminal dysuria.

	Mean $\pm$ SD
Age (years)	68.57 $\pm$ 7.98
Height (kg)	66.44 $\pm$ 8.91
Weight (cm)	166.76 $\pm$ 6.05
Body mass index (kg/m <sup>2</sup> )	23.82 $\pm$ 2.40
Prostate size (mL)	89.66 $\pm$ 22.36
Catheterization time (h)	43.72 $\pm$ 8.46
Operation time (min)	45.25 $\pm$ 8.92
Irrigation fluid (L)	16.05 $\pm$ 2.15
Prostate-specific antigen (ng/mL)	2.09 $\pm$ 0.48
Quality of life	4.48 $\pm$ 0.93
Blood loss (mL)	21.06 $\pm$ 11.52
Bladder irrigation time (hours)	18.76 $\pm$ 5.46
Hospital stay (days)	5.95 $\pm$ 1.81
<b>Post op Complications, n (%)</b>	
Yes, n (%)	86 (17.3)
No, n (%)	410 (82.7)
<b>Post op Complications (n=86)</b>	
Burning micturition, n (%)	46 (53.5)
Stress incontinence, n (%)	11 (12.8)
Terminal dysuria, n (%)	29 (33.7)

**Table-I. Characteristics of study population (n=496)  
SD; Standard Deviation**

Table-II demonstrates the comparison of preoperative outcomes at three and six follow up. Baseline mean maximum urinary flow rate (Qmax) was  $5.57 \pm 2.44$  mL/s, post void residual (PVR) was  $130.91 \pm 24.18$  mL, and international prostate symptom score (IPSS) was  $26.09 \pm 2.40$  at preoperative. At 3 months follow-up, Qmax was  $23.31 \pm 8.0$  mL/s, PVR was  $22.43 \pm 5.21$  mL

and IPSS was  $7.27 \pm 1.42$ . On the other hand, mean Qmax was  $25.83 \pm 6.84$  mL/s, PVR was  $18.38 \pm 4.53$  mL, and IPSS was  $5.29 \pm 0.61$  at 6 months follow-up. At 3 months and 6 months, significant improvement were observed with the p value of 0.001.

Table-III illustrates the laboratory parameters observed in preoperative and postoperative stage. Mean hemoglobin was  $13.02 \pm 0.81$  g/dl in perioperative and  $12.86 \pm 0.89$  g/dl in postoperative. There was significant

improvement in hemoglobin level was observed in postoperative with the p value of  $<0.001$ . Sodium in preoperative was  $141.27 \pm 2.12$  mmol/L and was  $138.66 \pm 1.68$  mmol/L in postoperative. Potassium and creatinine in preoperative were  $4.03 \pm 0.21$  mmol/L and  $1.09 \pm 0.16$  mg/dL while postoperative potassium and creatinine were  $3.62 \pm 0.26$  mmol/L and  $0.89 \pm 0.16$  mg/dL, respectively. Significant improvement in postoperative potassium and creatinine was observed with the p value of  $<0.001$ .

Parameter	Preoperative	3 months	Mean Difference	P-Value	6 Months	Mean Difference	P-Value
Qmax (mL/s)	$5.57 \pm 2.44$	$23.31 \pm 8.05$	17.7458	$<0.001$	$25.83 \pm 6.84$	20.27	$<0.001$
PVR (mL)	$130.91 \pm 24.18$	$22.43 \pm 5.21$	-108.48	$<0.001$	$18.38 \pm 4.53$	-112.54	$<0.001$
IPSS	$26.09 \pm 2.40$	$7.27 \pm 1.42$	-18.83	$<0.001$	$5.29 \pm 0.61$	-20.8	$<0.001$

**Table-II. Comparison of preoperative outcomes at three and six months (n=496)**  
Qmax;Maximum flow rate, PVR;Post void residual, IPSS;International prostate symptom score

Parameter	Preoperative	Postoperative	Mean Difference	P-Value
Sodium-Na (mmol/L)	$141.27 \pm 2.12$	$138.66 \pm 1.68$	2.60	$<0.001$
Potassium-K(mmol/L)	$4.03 \pm 0.21$	$3.62 \pm 0.26$	0.40	$<0.001$
Creatinine-Cr (mg/dL)	$1.09 \pm 0.16$	$0.89 \pm 0.16$	0.20	$<0.001$
Hemoglobin-Hb (g/dl)	$13.02 \pm 0.81$	$12.86 \pm 0.89$	0.16	$<0.001$

**Table-III. Preoperative and postoperative's laboratory parameters**

## DISCUSSION

Transurethral resection of the prostate (TURP) is widely recognized as the prevailing and benchmark approach for the surgical treatment of benign prostatic hyperplasia (BPH).<sup>7</sup> Several factors have been identified as being related with higher complication rates of transurethral resection of the prostate (TURP). These factors include the learning period, older age of patients, the presence of cardiac comorbidities, and hemostatic illnesses.<sup>8</sup> The most notable problems that persist include bleeding necessitating urethral stenosis, blood transfusion, lengthy catheterization durations, and TUR syndrome.<sup>9</sup> The elevated incidence of difficulties associated with this clinical outcome has necessitated the exploration of alternate procedures for prostate ablation that yield comparable clinical outcomes while minimizing complications. Among these surgical approaches, vaporization procedures and laser ablation, including KTP, diode, and HOLEP, exhibit considerable potential. It is challenging to select a suitable laser for the treatment of BPH but the necessary

consideration encompasses the mechanism, effectiveness, durability, catheterization time, rate of complications, duration of hospital stays, and cost-effectiveness.<sup>10</sup>

The study demonstrates that DVP using a diode laser at 980 nm is safe and efficacious in treating BPH as it reported fewer complications than TURP. In addition, DVP using a diode laser at 980 nm provided effective BPH outcomes with catheter indwelling times and shorter hospitalization stays. The findings of our study are in conjunction with the study by Kou et al. and indicated that a 50% prevalence of BPH was prevalent among men older than 50 years.<sup>11</sup> Despite TURP being considered the gold standard treatment approach for BPH, it become less preferable for BPH than PVP due to its significant drawbacks of TURS and bleeding.<sup>12</sup> It is evaluated in a study by Kim et al. that lasers have become extensively used for vaporization of the prostate, which provided better clinical efficacy and safety for high-risk patients with benign prostatic hyperplasia.<sup>13</sup>



The outcomes of the present study revealed that postoperative parameters are significantly improved with the treatment of BPH using a laser diode at 980 nm than PVP and DVP at 940nm and 1470nm. 980nm wavelength diode has shown improved absorption of water and hemoglobin, leading to better and quick tissue ablation with excellent hemostasis than 1470nm and 940nm.<sup>9</sup> One significant drawback of these lasers is their utilization of near-infrared wavelength, which results in coagulation necrosis due to their profound optical penetration.<sup>14</sup> The presence of necrotic tissue can lead to the manifestation of dysuria, sloughing, and persistent storage symptoms.<sup>15</sup> To address this issue, novel diode laser systems have been developed to minimize the extent of tissue penetration by controlling several parameters such as pulsation, frequency, power, and fiber design.<sup>16</sup> The implementation of a laser fiber with a quartz head contact has been employed to mitigate the depth of penetration, resulting in a reduction in the incidence of dysuria.<sup>17</sup> The comparable rates of bleeding, with values of 0.21-0.14g of hemoglobin per minute<sup>9</sup>, respectively, and our results are in conjunction with it, as depicted in Table-I. The diode laser exhibits a coagulation rim measuring 0.5 mm (with a range of 0.2–1 mm) when applied to prostate tissue, and it does not induce any hemorrhage.<sup>18</sup> The absorption of energy primarily occurs at the surface of prostatic tissue, resulting in enhanced ablative and hemostatic qualities. This effect remains significant even in patients who are undergoing oral anticoagulant therapy.<sup>19</sup> Hence, it is unnecessary to cease anticoagulant therapy prior to the procedure. In the context of the 980 nm diode laser, the rate of vaporization remains unaffected by the specific tissue type, whether it is mucosa or fibromuscular stroma.<sup>18,19</sup> This distinguishes the diode laser from other laser systems. In addition, the diode laser possesses the notable benefit of reduced energy consumption and obviates the need for high-voltage connections, hence enhancing the portability of the laser generator. Moreover, DVP offers several advantages, including reduced catheterization time and hospitalization duration without discontinuing anticoagulant treatment.<sup>20</sup>

Previous studies have documented a significant prevalence of dysuria and burning micturition.<sup>21</sup> The prevalence rates of dysuria and burning micturition in this study were 29% and 46%, respectively. In addition, a limited number of studies have documented elevated re-operation rates ranging from 8% to 33% and a persistent prevalence of stress urine incontinence at 9.1%, while we have found 11% stress incontinence.<sup>20</sup> Before diode laser vaporization, patients should undergo evaluation for prostate cancer using prostate-specific antigen (PSA) testing, digital rectal examination (DRE), and prostate biopsy if necessary. All individuals presenting with clinical suspicion of prostate cancer are not included in the study. Another disadvantage of diode lasers is their high cost, while the cost of laser treatment for benign prostatic hyperplasia (BPH) is lower than other alternatives, it remains more expensive than transurethral resection of the prostate (TURP).<sup>9</sup>

In conclusion, Diode vaporization of the prostate (DVP) with a diode laser has been shown as a secure and efficacious intervention for benign prostatic hyperplasia (BPH). Moreover, it has been demonstrated to be a safe therapeutic option even for concurrently receiving anti-platelet medicines. Its results show no significant difference between pre- and post-operative hemoglobin, less burning micturition, reduced rates of dysuria, and less urine incontinence. It is also a privilege for this study because it is one of the initial studies performed on diode laser vaporization for benign prostatic hyperplasia in Pakistan.

## CONCLUSION

Treatment of BPH by 980/1470 nm diode laser have effective and safe clinical outcome for high risk patients as we found significant improvements in Qmax, IPSS, and PVR at 3 months and 6 months follow up.

**Copyright© 31 Aug, 2023.**

## REFERENCES

1. Hueber P-A, Liberman D, Ben-Zvi T, Woo H, Hai MA, Te AE, et al. **180 W vs 120 W lithium triborate photoselective vaporization of the prostate for benign prostatic hyperplasia: A global, multicenter comparative analysis of perioperative treatment parameters.** *Urology.* 2013; 82(5):1108-13.

2. Ahari AM, Ghyassi FS, Yousefi M, Amjadi M, Mostafaie A. **Green light photo selective vaporization of the prostate vs. transurethral resection of prostate for benign prostatic hyperplasia.** *Journal of Lasers in Medical Sciences.* 2011; 2(4):152-8.
3. Qian X, Liu H, Xu D, Xu L, Huang F, He W, et al. **Functional outcomes and complications following B-TURP versus HoLEP for the treatment of benign prostatic hyperplasia: A review of the literature and Meta-analysis.** *The Aging Male.* 2017; 20(3):184-91.
4. Majumdar R, Mirheydar HS, Palazzi KL, Lakin CM, Albo ME, Parsons JK. **Prostate laser vaporization is safe and effective in elderly men.** *Urology annals.* 2015; 7(1):36-40.
5. Mithani MH, El Khalid S, Khan SA, Sharif I, Awan AS, Mithani S, et al. **Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: A prospective study.** *Investigative and Clinical Urology.* 2018; 59(6):392-8.
6. Cetinkaya M, Önem K, Rifaioğlu MM, Yalçın V. **980-Nm diode laser vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: Randomized controlled study.** 2015; 12(5):2355-61.
7. Couteau N, Duquesne I, Frédéric P, Thiounn N, Timsit MO, Mejean A, et al., **Ejaculations and benign prostatic hyperplasia: An impossible compromise? A comprehensive review.** *J Clin Med.* 2021; 10(24):5788.
8. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al., **Benign prostatic hyperplasia.** *Nat Rev Dis Primers.* 2016; 2(1):1-5.
9. Mithani MH, El Khalid S, Khan SA, Sharif I, Awan AS, Mithani S, et al., **Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: A prospective study.** *Investig Clin Urol.* 2018; 59(6):392-8.
10. Westwood J, Geraghty R, Jones P, Rai BP, Somani BK. **Rezūm: A new transurethral water vapour therapy for benign prostatic hyperplasia.** *Ther Adv Urol.* 2018; 10(11):327-33.
11. Kuo YJ, Sung FC, Hsieh PF, Chang HP, Wu KL, Wu HC. **Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.** *Cancer Med.* 2019; 8(5):2514-23.
12. Sun F, Sun X, Shi Q, Zhai Y. **Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications.** *Med.* 2018; 97(51):e13360.
13. Kim M, Song SH, Ku JH, Kim HJ, Paick JS. **Pilot study of the clinical efficacy of ejaculatory hood sparing technique for ejaculation preservation in Holmium laser enucleation of the prostate.** *Intl J Impot Res.* 2015; 27(1):20-4.
14. Schena E, Saccomandi P, Fong Y. **Laser ablation for cancer: Past, present and future.** *J Funct Biomater.* 2017; 8(2):19.
15. Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR. **The Rezūm system—a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia.** *Can J Urol.* 2019; 26(3):9787-93.
16. Jiang DL, Yang Z, Liu GX, Wu K, Fan J, Wu D, et al., **A novel 450-nm blue laser system for surgical applications: Efficacy of specific laser-tissue interactions in bladder soft tissue.** *Lasers Med Sci.* 2019; 34:807-13.
17. Yilmaz M, Heuring CE, Schoeb D, Suarez-Ibarrola R, Gratzke C, Hein S, et al., **In vivo temperature assessment during holmium laser enucleation of the prostate.** *Urologia Internationalis.* 2023; 107(4):363-9.
18. Zhou Z, Cui Y, Zhang X, Zhang Y. **Comparison of 532-nm GreenLight HPS laser with 980-nm diode laser vaporization of the prostate in treating patients with lower urinary tract symptom secondary to benign prostatic hyperplasia: A meta-analysis.** *Lasers Med Sci.* 2021; 1-1.
19. He G, Shu Y, Wang B, Du C, Chen J, Wen J. **Comparison of diode laser (980 nm) enucleation vs holmium laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: A randomized controlled trial with 12-month follow-up.** *Journal Endourol.* 2019; 33(10):843-9.
20. Razzaghi MR, Mazloomfard MM, Mokhtarpour H, Moeini A. **Diode laser (980 nm) vaporization in comparison with transurethral resection of the prostate for benign prostatic hyperplasia: Randomized clinical trial with 2-year follow-up.** *Urol.* 2014; 84(3):526-32.
21. Sanjo T, Tanaka N, Shinojima T, Yasumizu Y, Takeda T, Matsumoto K, et al., **Endoscopic vaporization of benign prostatic hyperplasia using a contact 980 nm diode laser under antithrombotic therapy: A prospective survey.** *Asian J Endosc Surg.* 2022;15(3):585-90.

**AUTHORSHIP AND CONTRIBUTION DECLARATION**

No.	Author(s) Full Name	Contribution to the paper	Author(s) Signature
1	Shahid Ali	Autor	